April 2nd, 2020  | article

Aaron Cowley Talks Process Development of LBPs

As an inorganic chemistry student at Benedictine College, Aaron Cowley, Arranta Bio’s Chief Scientific Officer, didn’t expect to someday lead a biotechnology company focused on the process development of LBPs. Even as a doctoral and post-doctoral student, Aaron’s passion was the potential therapeutic nature of enzymes, which led him to start Captozyme, a CDMO supporting…

Read More

January 30th, 2020  | Press Release

Arranta Bio announces key leadership additions of Chief Operations Officer and SVP of Business Development as it commits to a $100M investment in building end-to-end microbiome capacity

Watertown, MA – January 28, 2020: Arranta Bio (“Arranta”), the leading microbiome contract development and manufacturing organization (CDMO), announced today the strengthening of its senior leadership team with the addition of David Stevens as Chief Operations Officer and Jason Rahal as Senior Vice President of Business Development. Arranta has committed $100M to build end-to-end capacity…

Read More

November 13th, 2019  | Press Release

Arranta Bio announces the acquisition of Captozyme™, creating a Center of Excellence for microbiome development and clinical supply

Watertown, MA – November [13], 2019: Arranta Bio (“Arranta”) announced today the acquisition of Captozyme™, and with it the establishment of Arranta’s Center of Excellence for process and analytical development and early clinical supply for microbiome clients with the transfer of the Captozyme team and facilities in Gainesville, FL to Arranta.  Formed in 2009, Captozyme has…

Read More

October 29th, 2019  | Press Release

Arranta Bio announces $82M in new funding, and a strategic partnership with Thermo Fisher Scientific

Watertown, MA – October 29, 2019: Arranta Bio (“Arranta”) announced today the completion of an $82 million funding round and a strategic partnership with Thermo Fisher Scientific.  Formed in May 2019, Arranta’s goal is to be the best-in-class microbiome contract development and manufacturing organization (CDMO). The business provides live biopharmaceutical products (LBPs) for microbiome pioneers by…

Read More
As an essential business under State and local government orders in MA and FL, Arranta Bio’s development and manufacturing services for the pharmaceutical industry continue during the COVID-19 pandemic. Our laboratories and GMP facilities have remained open with reduced staffing and enhanced safety precautions, as have our construction projects. The well-being and safety of our employees, vendors, partners, and clients is of utmost importance to us and we continue to monitor all developments.